This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ko, H.-J. Articles by Kang, C.-Y. Search for Related Content PubMed PubMed Citation Articles by Ko, H.-J. Articles by Kang, C.-Y.

A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model

¹ Laboratory of Immunology, Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, Korea; and ² Department of Experimental Pathology, Institute for Frontier Medical Science, Kyoto University, Kyoto, Japan

Requests for reprints: Chang-Yuil Kang, Laboratory of Immunology, College of Pharmacy, Seoul National University, Shillim-9-dong, Kwanak-gu, Seoul 151-742, Korea. Phone: 82-2-880-7860; Fax: 82-2-885-1373; E-mail: cykang{at}snu.ac.kr.

Her-2/neu is a well-characterized tumor-associated antigen overexpressed in human carcinomas such as breast cancer. Because Her-2/neu is a self-antigen with poor immunogenicity due to immunologic tolerance, active immunotherapy targeting Her-2/neu should incorporate methods to overcome immunologic tolerance to self-proteins. In this study, we developed a tolerogenic tumor model in mice using mouse Her-2/neu as self-antigen and investigated whether genetic vaccination with DNA plasmid and/or adenoviral vector expressing the extracellular and transmembrane domain of syngeneic mouse Her-2/neu or xenogenic human Her-2/neu could induce mouse Her-2/neu–specific CTL responses. Interestingly, adenoviral vectors expressing xenogenic human Her-2/neu (AdhHM) proved capable of breaking immune tolerance and of thereby inducing self-reactive CTL and antibodies, but not to the degree required to induce therapeutic antitumor immunity. In attempting to generate therapeutic antitumor immunity against established tumors, we adopted several approaches. Treatment with agonistic anti-glucocorticoid-induced TNFR family-related receptor (GITR) antibody plus AdhHM immunization significantly increased self-reactive CTL responses, and -galactosylceramide (GalCer)–loaded dendritic cells (DC) transduced with AdhHM were shown to break self-tolerance in a tolerogenic murine tumor model. Furthermore, gemcitabine treatment together with either AdhHM plus agonistic anti-GITR antibody administration or GalCer-loaded DC transduced with AdhHM showed potent therapeutic antitumor immunity and perfect protection against preexisting tumors. Gemcitabine treatment attenuated the tumor-suppressive environment by eliminating CD11b⁺/Gr-1⁺ myeloid-derived suppressor cells. When combined with immunotherapies, gemcitabine offers a promising strategy for the Ag-specific treatment of human cancer. [Cancer Res 2007;67(15):7477–86]

This article has been cited by other articles:

				G. V. Shurin, I. L. Tourkova, R. Kaneno, and M. R. Shurin Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism J. Immunol., July 1, 2009; 183(1): 137 - 144. [Abstract] [Full Text] [PDF]

				J. Ozao-Choy, G. Ma, J. Kao, G. X. Wang, M. Meseck, M. Sung, M. Schwartz, C. M. Divino, P.-Y. Pan, and S.-H. Chen The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies Cancer Res., March 15, 2009; 69(6): 2514 - 2522. [Abstract] [Full Text] [PDF]

				H.-J. Ko, J.-M. Lee, Y.-J. Kim, Y.-S. Kim, K.-A Lee, and C.-Y. Kang Immunosuppressive Myeloid-Derived Suppressor Cells Can Be Converted into Immunogenic APCs with the Help of Activated NKT Cells: An Alternative Cell-Based Antitumor Vaccine J. Immunol., February 15, 2009; 182(4): 1818 - 1828. [Abstract] [Full Text] [PDF]

				H.-J. Ko, J.-Y. Yang, D.-H. Shim, H. Yang, S.-M. Park, R. Curtiss III, and M.-N. Kweon Innate Immunity Mediated by MyD88 Signal Is Not Essential for Induction of Lipopolysaccharide-Specific B Cell Responses but Is Indispensable for Protection against Salmonella enterica serovar Typhimurium infection J. Immunol., February 15, 2009; 182(4): 2305 - 2312. [Abstract] [Full Text] [PDF]

				B. Liu, Z. Li, S. P. Mahesh, S. Pantanelli, F. S. Hwang, W. O. Siu, and R. B. Nussenblatt Glucocorticoid-induced Tumor Necrosis Factor Receptor Negatively Regulates Activation of Human Primary Natural Killer (NK) Cells by Blocking Proliferative Signals and Increasing NK Cell Apoptosis J. Biol. Chem., March 28, 2008; 283(13): 8202 - 8210. [Abstract] [Full Text] [PDF]